Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00.

France's CGT and CFDT unions have called on workers at pharma company Sanofi to strike from Thursday to show their protest ...

In a report released yesterday, Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), ...

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...

The proposal from PAI Partners, challenging a US bidder, is the latest twist in a battle to win a 50% stake in Opella, the ...

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to ...

A consortium led by French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's consumer health ...

The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...